

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

REGENERON PHARMACEUTICALS, INC.,
Appellant

v.

**MYLAN PHARMACEUTICALS INC., CELLTRION,
INC., SAMSUNG BIOEPIS CO., LTD.,**
Appellees

2024-1564, 2024-1567

Appeals from the United States Patent and Trademark
Office, Patent Trial and Appeal Board in Nos. IPR2022-
01225, IPR2022-01226, IPR2023-00532, IPR2023-00533,
and IPR2023-00566.

ON MOTION

O R D E R

Upon consideration of Regeneron Pharmaceuticals,
Inc.'s unopposed motion to voluntarily dismiss the above-
captioned appeals pursuant to Federal Rule of Appellate
Procedure 42,

2

REGENERON PHARMACEUTICALS, INC. v. MYLAN
PHARMACEUTICALS INC.

IT IS ORDERED THAT:

(1) The motion is granted, and the appeals are dismissed.

(2) Each party shall bear its own costs for each appeal.

FOR THE COURT



Jarrett B. Perlow
Clerk of Court

August 20, 2024
Date

ISSUED AS A MANDATE: August 20, 2024